LU93315I2 - Procédé de traitement de la sclérose multiple - daclizumab - Google Patents

Procédé de traitement de la sclérose multiple - daclizumab Download PDF

Info

Publication number
LU93315I2
LU93315I2 LU93315C LU93315C LU93315I2 LU 93315 I2 LU93315 I2 LU 93315I2 LU 93315 C LU93315 C LU 93315C LU 93315 C LU93315 C LU 93315C LU 93315 I2 LU93315 I2 LU 93315I2
Authority
LU
Luxembourg
Prior art keywords
daclizumab
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
LU93315C
Other languages
English (en)
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93315(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of LU93315I2 publication Critical patent/LU93315I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
LU93315C 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab LU93315I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (fr) 2002-06-28 2002-11-27 Procede de traitement de maladies auto-immunes au moyen d'interferon beta et de l'antagoniste du il-2r
PCT/US2003/020428 WO2004002421A2 (fr) 2002-06-28 2003-06-27 Procede de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
LU93315I2 true LU93315I2 (fr) 2017-01-26

Family

ID=30000962

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93315C LU93315I2 (fr) 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab

Country Status (15)

Country Link
US (11) US7575742B2 (fr)
EP (3) EP2314627B1 (fr)
JP (8) JP2005535636A (fr)
AU (3) AU2002368055B2 (fr)
CA (3) CA2490804C (fr)
CY (2) CY2016043I1 (fr)
DK (2) DK1539200T3 (fr)
ES (2) ES2637011T3 (fr)
HK (1) HK1249850A1 (fr)
HU (2) HUE036677T2 (fr)
IL (2) IL165973A (fr)
LU (1) LU93315I2 (fr)
PT (2) PT2314627T (fr)
SI (2) SI1539200T1 (fr)
WO (2) WO2004002500A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101526127B (zh) * 2001-04-26 2011-08-17 瀑溪技术公司 连续可变变速器及部件支撑件、支撑框架及框架制作方法
WO2004002500A1 (fr) 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de traitement de maladies auto-immunes au moyen d'interferon beta et de l'antagoniste du il-2r
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
CN107028760B (zh) * 2005-01-12 2019-11-01 比奥根Ma公司 运输干扰素-β的方法
WO2006089066A1 (fr) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Polytherapie pour le traitement d'etats de demyelinisation
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
JP2012505257A (ja) * 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド 多発性硬化症治療のための組成物および方法
WO2010068923A2 (fr) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents inhibant sélectivement cd25 sur des cellules dendritiques ou des lymphocytes t et leur utilisation
EP2473851A1 (fr) * 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Utilisation d'une population de cellules nk immunorégulatrices pour surveiller l'efficacité d'anticorps anti-il-2r chez des patients atteints d'une sclérose en plaques
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
WO2015089217A2 (fr) 2013-12-10 2015-06-18 Bionz, Llc Procédés de développement d'antagonistes peptidiques sélectifs
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
WO2013022972A1 (fr) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Procédés de traitement de formes progressives de la sclérose en plaques
EP3359556B1 (fr) 2015-10-09 2021-05-26 Bioniz, LLC Modulation de l'activité des cytokines gamma-c
WO2018027195A1 (fr) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions contenant des quantités réduites d'isoformes acides de daclizumab et procédés de préparation associés
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf
KR20240142577A (ko) 2017-04-07 2024-09-30 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
JP2022530677A (ja) 2019-05-03 2022-06-30 バイオニズ リミテッド ライアビリティー カンパニー 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節
JP2022544169A (ja) * 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5747444A (en) * 1990-10-09 1998-05-05 Chiron Corporation Method of treating graft-versus-host disease
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
JPH09501891A (ja) 1993-08-27 1997-02-25 ザ ピルスベリー コムパニー 機械的なガスフラッシュ装置
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
WO1996002555A1 (fr) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
AU3710597A (en) * 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
WO2000025816A1 (fr) 1998-10-30 2000-05-11 The University Of Miami Traitement de l'hepatite c par administration d'un anticorps monoclonal anti recepteur de il-2 et d'un compose antiviral
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
JP3538616B2 (ja) 2000-04-25 2004-06-14 友昭 星野 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
WO2002081508A2 (fr) * 2001-04-06 2002-10-17 University Of Bristol Utilisation de molecules de liaison cd25 chez des patients resistants aux steroides
WO2004002500A1 (fr) 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de traitement de maladies auto-immunes au moyen d'interferon beta et de l'antagoniste du il-2r
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production

Also Published As

Publication number Publication date
AU2008212004B2 (en) 2010-10-21
US20130017152A1 (en) 2013-01-17
US8298525B2 (en) 2012-10-30
CA2490804C (fr) 2016-12-06
IL165973A (en) 2015-10-29
JP2010132660A (ja) 2010-06-17
US20150337044A1 (en) 2015-11-26
HUS1600050I1 (hu) 2017-06-28
JP2016145220A (ja) 2016-08-12
SI1539200T1 (sl) 2014-09-30
SI2314627T1 (sl) 2017-10-30
US7575742B2 (en) 2009-08-18
US20170190779A1 (en) 2017-07-06
CY1119389T1 (el) 2018-02-14
EP2314627B1 (fr) 2017-07-26
EP2314627A2 (fr) 2011-04-27
PT1539200E (pt) 2014-08-25
US20050249704A1 (en) 2005-11-10
US20080038275A1 (en) 2008-02-14
HK1249850A1 (en) 2018-11-16
AU2002368055A1 (en) 2004-01-19
IL165973A0 (en) 2006-01-15
US8454965B2 (en) 2013-06-04
AU2003247813B2 (en) 2008-06-05
EP1539200A4 (fr) 2007-11-07
WO2004002421A3 (fr) 2004-09-02
CA2490804A1 (fr) 2004-01-08
CA2490186C (fr) 2014-04-15
DK1539200T3 (da) 2014-06-30
US8636997B2 (en) 2014-01-28
US20180237532A1 (en) 2018-08-23
US20130095069A1 (en) 2013-04-18
AU2003247813C1 (en) 2010-07-22
JP2011157378A (ja) 2011-08-18
AU2008212004A1 (en) 2008-09-25
ES2637011T3 (es) 2017-10-10
EP1539200A2 (fr) 2005-06-15
HK1074769A1 (en) 2005-11-25
CY2016043I2 (el) 2017-04-05
JP5905534B2 (ja) 2016-04-20
HUE036677T2 (hu) 2018-07-30
CA2844639A1 (fr) 2004-01-08
WO2004002421A2 (fr) 2004-01-08
US20190002575A1 (en) 2019-01-03
JP2005535636A (ja) 2005-11-24
AU2003247813A1 (en) 2004-01-19
JP2013032372A (ja) 2013-02-14
JP2013139478A (ja) 2013-07-18
JP2006508039A (ja) 2006-03-09
US20090175823A1 (en) 2009-07-09
EP2314627A3 (fr) 2011-05-11
DK2314627T3 (en) 2017-10-23
EP3269377A1 (fr) 2018-01-17
JP2014221813A (ja) 2014-11-27
PT2314627T (pt) 2017-08-29
IL241920A0 (en) 2015-11-30
US7258859B2 (en) 2007-08-21
CY2016043I1 (el) 2017-04-05
US20150010477A1 (en) 2015-01-08
WO2004002500A1 (fr) 2004-01-08
ES2474718T3 (es) 2014-07-09
US20040109859A1 (en) 2004-06-10
EP1539200B1 (fr) 2014-05-28
AU2002368055B2 (en) 2008-09-18
CA2490186A1 (fr) 2004-01-08

Similar Documents

Publication Publication Date Title
PL1655036T3 (pl) Sposób leczenia chorób onkologicznych
EP1545700A4 (fr) Methode de traitement de degats du systeme nerveux central
EP1511508A4 (fr) Methode de traitement de troubles dyslipidemiques
IL175818A0 (en) Method for treating adamts-5- associated disease
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
EP1539200A4 (fr) Procede de traitement de la sclerose multiple
FR2814945B1 (fr) Procede de traitement de la canitie
FI20020479A0 (fi) Pintakäsittelyprosessi
EP1489506A4 (fr) Systeme de traitement decentralise, procede et programme de traitement decentralise de travaux
FI20040011L (fi) Menetelmä pintojen käsittelemiseksi
EP1492902A4 (fr) Composition et procede de traitement de surfaces metalliques
FI20020817A7 (fi) Pintakäsittelyprosessi
FI20012170L (fi) Menetelmä lauhteiden käsittelemiseksi
FI20020942A0 (fi) Menetelmä tärkkelyksen käsittelemiseksi
FI20022150A7 (fi) Menetelmä kuonan käsittelemiseksi
FI20030380L (fi) Menetelmä prosessin säätämiseksi
FI20030735A0 (fi) Menetelmä ja laite veden käsittelemiseksi
BR0312187B1 (pt) método para o tratamento de sementes
FI20030497A0 (fi) Menetelmä jätehapon käsittelemiseksi
EP1599193A4 (fr) Methode de traitement de l'hypothyroïdie
FI20030736A0 (fi) Menetelmä ja laite veden käsittelemiseksi
FI20020849A0 (fi) Menetelmä tekstiilin käsittelyyn
FI20030381L (fi) Menetelmä prosessin säätämiseksi
FR2853309B1 (fr) Procede et installation de traitement de dejections animales
ITMI20020809A1 (it) Metodo per la selezione di composti utili nel trattamento della coreadi huntington